- Home
- ENTA vs CANG Comparison
ENTA vs CANG Comparison
Compare ENTA & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTA | CANG |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 457.2M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ENTA | CANG |
|---|---|---|
| Price | $12.85 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.40 | $3.00 |
| AVG Volume (30 Days) | 283.1K | ★ 941.1K |
| Earning Date | 02-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $65,324,000.00 | ★ $621,628,844.00 |
| Revenue This Year | $0.99 | $4,371.16 |
| Revenue Next Year | $0.19 | $13.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1534.99 |
| 52 Week Low | $4.09 | $1.12 |
| 52 Week High | $17.15 | $2.10 |
Technical Indicators
Market Signals| Indicator | ENTA | CANG |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 42.78 |
| Support Level | $12.09 | $1.34 |
| Resistance Level | $13.98 | $1.47 |
| Average True Range (ATR) | 0.73 | 0.13 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 19.01 | 10.71 |
Price Performance
Historical ComparisonAbout ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.